Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia, ...
Presentations at Association for Molecular Pathology 2025 Annual Meeting Spotlight Clinical Impact of Delve Bio’s Metagenomic Sequencing Test for Improving CNS Diagnosis Delve Detect delivers 22 ...
Leveraging their combined expertise and influence, the group drives transformative change, ensuring that cutting-edge innovations shape the future of digital pathology. Presentations by Pathology ...
Case Presentation Conclusion: How and Why Did We Treat? What Were the Outcomes? Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by ...
Delve Detect delivers 22 percent greater diagnostic yield with results the next day, offering an important new tool for managing complex central nervous system infections, including co-infection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results